X

Trial Profile

A Phase 1, Randomized, Open-Label, Three-Way Crossover Study of Two Oral Formulations of LX4211 in Subjects With Type 2 Diabetes Mellitus.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 03 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sotagliflozin (Primary)
Indications Type 2 diabetes mellitus
Focus Pharmacokinetics

Most Recent Events

27 Jun 2012 Results published in the Clinical Pharmacology and Therapeutics.
16 Sep 2011 Results presented at the 47th Annual Meeting of the European Association for the Study of Diabetes.
28 Jun 2011 Results presented at the 71st Annual Scientific Sessions of the American Diabetes Association.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com